Immune tolerance treatment in haemophilia patients with inhibitors: The Spanish registry

Haemophilia

Volumn 7, Issue 2, 2001, Pages 154-159

  Haya, S ^a   Lopez M F ^a   Aznar, J A ^a,b   Batlle, J ^a  

^a HOSPITAL UNIVERSITARIO LA FE   (Spain)

^b Haematology Service   (Spain)

Author keywords

Haemophilia; Immune tolerance; Immune tolerance treatment; Inhibitors

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 INHIBITOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG PURITY; HEMOPHILIA; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INFANT; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; SPAIN; TREATMENT OUTCOME;

ACTUARIAL ANALYSIS; ADOLESCENT; ADULT; AGE OF ONSET; CHILD; CHILD, PRESCHOOL; FACTOR IX; FACTOR VIII; HEMOPHILIA A; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; ISOANTIBODIES; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SPAIN;

EID: 0035082871     PISSN: 13518216     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2516.2001.00469.x     Document Type: Article

References (28)

1. Haemophilia with factor VIII inhibitors in Finland: Prevalence, incidence and outcome
2. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs
3. Factor VIII and factor IX inhibitors in haemophiliacs
4. Frequency of inhibitor development in haemophiliacs treated with low purity factor VIII
5. Incidence of factor VIII inhibitor development in haemophilia A patients treated with less pure plasma-derived concentrates
6. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia
7. Multicenter study of recombinant factor VIII (Recombinate): Safety, efficacy, and inhibitor risk in previously untreated patients with hemophilia A
8. Prevalence of factor IX inhibitors among patients with haemophilia B. Results of a large-scale North American survey
9. Safety and immunogenicity of recombinant factor VIII (Recombinate) in previously untreated patients (PUPs): A 6.5 year update. XVI Congress of the International Society on Thrombosis and Haemostasis, Florence
10. Inhibitor incidence in previously untreated patients (PUPs) with hemophilia A and B. XXIII Congress of the World Federation of Hemophilia, The Hague
11. Prevalence of inhibitors in a population of 3435 hemophilia patients in France
12. Recombinant FVIII (Kogenate) treatment of previously untreated patients (PUPs) with hemophilia A. Update of safety, efficacy and inhibitor development after seven study years. XVI Congress of the International and Haemostasis, Florence
13. Massive factor VIII infusion in hemophiliac with factor VIII inhibitors, high responder
14. The importance of corticoids added to continued treatment with factor VIII concentrates in the suppression of inhibitors in haemophilia A
15. Induction of immune tolerance to factor VIII in hemophilia with inhibitors
16. Disappearance of factor VIII:C antibodies in patients with haemophilia A upon frequent administration of factor VIII in intermediate or low dose
17. Low-dose immune tolerance induction in hemophilia A patients with inhibitors
18. Immune tolerance
19. Tolerance induction using the Malmö treatment model 1982-95
20. Immune tolerance in hemophilia - Principal results from the International Registry
21. Analysis of the North American Immune Tolerance Registry (NAITR) 1993-97 Current practice implications. Thirty-Ninth Annual Meeting of the American Society of Hematology
22. Continuous high-dose factor VIII for the induction of immune tolerance in hemophilia A patients with high responder state: A description of eleven patients treated
23. Immune tolerance for the treatment of factor VIII inhibitors - Twenty years' 'Bonn Protocol'
24. The German National Immune Tolerance Registry, 1997 update
25. Variation in factor inhibitor reactivity with different commercial factor VIII preparations
26. Factor VIII inhibitor antibodies with C2 domain specificity are less inhibitory to factor complexed with von Willebrand factor
27. Successful immunetolerance therapy of FVIII-inhibitor in children after changing from high to intermediate purity FVIII concentrate. XXII International Congress of the World Federation of Hemophilia, Dublin
28. International Immune Tolerance Registry, 1997 update